Skip to content
S1267Senate2023-2024 SessionSame asA901

Limit Step Therapy Requirements

Official title

“Requires a utilization review agent to follow certain rules when establishing a step therapy protocol”

Sponsor Neil D. BreslinSD-46+4 co-sponsorsAffects Finance
Status
Signed by Governor
Impact
7/10
Significant
Outcome
Signed into law

Bill progress

Signed into law

What's happening

This bill restricts insurance step therapy protocols, setting new requirements for patient access to prescription drugs and override processes.

Why it matters

  1. Limits on Step Therapy Requirements. The bill restricts insurers from forcing patients to try more than two drugs in the same category before accessing the medicine their doctor originally prescribed, reducing unnecessary delays in effective treatment.

  2. Patient Protections for Continuity of Care. If a patient has already completed step therapy under a previous health plan or has been successfully treated with a drug in the past year, insurers can't require them to repeat the process or switch to less-preferred drugs, protecting patients who change insurance or face formulary changes.

  3. Evidence-Based and FDA-Approved Mandates. Insurers cannot require patients to try drugs that aren't FDA-approved for the specific condition or aren't supported by up-to-date, evidence-based guidelines, ensuring patients are only subjected to medically appropriate treatments.

  4. Streamlined Overrides and Provider Authority. The bill obligates insurers to accept doctors' written statements that a drug has failed as sufficient proof, and requires prompt coverage when a step therapy override is granted—making it easier for patients and doctors to bypass step therapy when clinically justified.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Health insurers and utilization review agents

    The bill would limit step therapy to no more than two failed drugs within one therapeutic category and make noncompliance with its requirements grounds for an override, absent fraud.

  • Patients prescribed drugs subject to step therapy

    The bill would bar step therapy when no therapeutic equivalent is available or the plan documents coverage of the drug within the past 365 days.

  • Patients switching health plans

    The bill would prevent repeat step therapy when the patient or provider documents completion of the prior plan’s protocol within the past 365 days.

  • Prescribing health care professionals

    The bill would require reviewers to accept their written or electronic attestations that a required drug failed as prima facie evidence of that failure.

Headline styles

Limit Step Therapy Requirements

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Neil D. Breslin

Senator · Senate District 46

Chair, Ethics And Internal GovernanceChair, Insurance

History

  1. Approval memo.72
  2. Signed chap.641
  3. Delivered to governor
  4. Returned to senate
  5. Passed assembly
  6. Ordered to third reading rules cal.299
  7. Substituted for A901A
  8. Referred to insurance
  9. Returned to assembly
  10. Repassed senate
  11. Amended on third reading 1267a
  12. Vote reconsidered - restored to third reading
Show 17 earlier actions
  1. Returned to senate
  2. Recalled from assembly
  3. Referred to insurance
  4. Delivered to assembly
  5. Passed senateVote 60–2
  6. Advanced to third reading
  7. 2nd report cal.
  8. 1st report cal.92
  9. Referred to insurance
  10. Returned to senate
  11. Died in assembly
  12. Referred to insurance
  13. Delivered to assembly
  14. Passed senateVote 59–3
  15. Ordered to third reading cal.85
  16. Reported and committed to rules
  17. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A901Assembly

Limit Step Therapy Rules

Assembly Floor Calendar · Sponsor John T. McDonald III

Impact 8 · Significant0% to pass

Full text

3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

1267--A Cal. No. 92

2023-2024 Regular Sessions

IN SENATE

January 11, 2023

Introduced by Sens. BRESLIN, ADDABBO, FERNANDEZ, MAY, SKOUFIS -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance -- recommitted to the Committee on Insurance in accordance with Senate Rule 6, sec. 8 -- reported favorably from said committee, ordered to first and second report, ordered to a third reading, passed by Senate and delivered to the Assembly, recalled, vote reconsidered, restored to third reading, amended and ordered reprinted, retaining its place in the order of third reading

AN ACT to amend the insurance law and the public health law, in relation to requiring a utilization review agent to follow certain rules when establishing a step therapy protocol

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subsection (a) of section 4902 of the insurance law is amended by adding two new paragraphs 15 and 16 to read as follows:

(15) When establishing a step therapy protocol, a utilization review agent shall ensure that the protocol cannot:

(i) require a prescription drug that has not been approved by the United States Food and Drug Administration for the medical condition being treated and/or is not supported by current evidence-based guidelines for the medical condition being treated;

(ii) require an insured to try and fail on more than two drugs within one therapeutic category before providing coverage to the insured for the prescribed drug;

(iii) require the use of a step therapy-required drug for longer than thirty days or a duration of treatment supported by current evidencebased treatment guidelines appropriate to the specific disease state being treated;

(iv) be imposed on an insured if a therapeutic equivalent to the prescribed drug is not available, or if the health plan has documenta-

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD02501-05-4

tion that it has covered the drug for the enrollee within the past three hundred sixty-five days;

(v) require a newly enrolled insured to repeat step therapy for a prescribed drug where that insured already completed step therapy for that drug under a prior plan, so long as the enrollee or provider submits information demonstrating completion of a step therapy protocol of the prior plan within the past three hundred sixty-five days; and

(vi) be imposed on an insured for a prescribed drug that was previously approved for coverage by a plan for a specific medical condition after the insured's plan implements a formulary change or utilization management that impacts the coverage criteria for the prescribed drug until the approved override expires, unless a specifically identified and current evidence-based safety concern exists and a different therapeutic alternative drug exists.

(16) When establishing a step therapy protocol, a utilization review agent shall ensure that the protocol accepts any written or electronic attestation submitted by the insured's health care professional as defined in section four thousand nine hundred of this title stating that a required drug has failed as prima facie evidence that the required drug has failed.

§ 2. Subsections (c-3) and (g) of section 4903 of the insurance law, subsection (c-3) as added and subsection (g) as amended by chapter 512 of the laws of 2016, are amended to read as follows:

(c-3) Upon a determination that the step therapy protocol should be overridden, the health plan shall authorize immediate coverage for the prescription drug prescribed by the insured's treating health care professional. Any approval of a step therapy protocol override determination request shall be honored until the lesser of either treatment duration based on current evidence-based treatment guidelines or twelve months following the date of the approval of the request or renewal of the insured's coverage.

(g) Failure by the utilization review agent to make a determination within the time periods prescribed in this section shall be deemed to be an adverse determination subject to appeal pursuant to section four thousand nine hundred four of this title, provided, however, that failure to meet such time periods for a step therapy protocol as defined in subsection (g-9) of section forty-nine hundred of this title or a step therapy protocol override determination pursuant to subsections (c-1), (c-2) and (c-3) of this section shall be deemed to be an override of the step therapy protocol. A utilization review agent's failure to comply with any of the step therapy protocol requirements required in subsections fifteen and sixteen of section four thousand nine hundred two of this title shall be considered a basis for granting an override of the step therapy protocol, absent fraud.

§ 3. Section 4902 of the public health law is amended by adding two new subdivisions 5 and 6 to read as follows:

5. When establishing a step therapy protocol, a utilization review agent shall ensure that the protocol cannot:

(a) require a prescription drug that has not been approved by the United States Food and Drug Administration and/or is not supported by current evidence-based guidelines for the medical condition being treated;

(b) require an enrollee to try and fail on more than two drugs within one therapeutic category before providing coverage to the insured for the prescribed drug;

(c) require the use of a step therapy-required drug for longer than thirty days or a duration of treatment supported by current evidencebased treatment guidelines appropriate to the specific disease state being treated;

(d) be imposed on an enrollee if a therapeutic equivalent to the prescribed drug is not available; or if the health plan has documentation that it has covered the drug for the enrollee within the past three hundred sixty-five days;

(e) require a newly enrolled enrollee to repeat step therapy for a prescribed drug where that enrollee already completed step therapy for that drug under a prior plan, so long as the enrollee or provider submit information demonstrating completion of a step therapy protocol of the prior plan within the past three hundred sixty-five days; and

(f) be imposed on an enrollee for a prescribed drug that was previously approved for coverage by a plan for a specific medical condition after the enrollee's plan implements a formulary or utilization management change that impacts the coverage criteria for the prescribed drug until the approved override expires, unless a specifically identified and evidence-based safety concern exists and a different therapeutic alternative drug exists.

6. When establishing a step therapy protocol, a utilization review agent shall ensure that the protocol accepts any written or electronic attestation submitted by the enrollee's health care professional as defined in section forty-nine hundred of this title stating that a required drug has failed as prima facie evidence that the required drug has failed.

§ 4. Subdivisions 3-c and 7 of section 4903 of the public health law, subdivision 3-c as added and subdivision 7 as amended by chapter 512 of the laws of 2016, are amended to read as follows:

3-c. Upon a determination that the step therapy protocol should be overridden, the health plan shall authorize immediate coverage for the prescription drug or drugs prescribed by the enrollee's treating health care professional. Any approval of a step therapy protocol override determination request shall be honored until the lesser of either treatment duration based on current evidence-based treatment guidelines or twelve months following the date of the approval of the request or renewal of the enrollee's coverage.

7. Failure by the utilization review agent to make a determination within the time periods prescribed in this section shall be deemed to be an adverse determination subject to appeal pursuant to section fortynine hundred four of this title, provided, however, that failure to meet such time periods for a step therapy protocol as defined in subdivision seven-f-three of section forty-nine hundred of this title or a step therapy protocol override determination pursuant to subdivisions three-a, three-b and three-c of this section shall be deemed to be an override of the step therapy protocol. A utilization review agent's failure to comply with any of the step therapy protocol requirements required in subdivisions five and six of section forty-nine hundred two of this title shall be considered a basis for granting an override of the step therapy protocol, absent fraud.

§ 5. This act shall take effect on the one hundred twentieth day after it shall have become a law.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law and the public health law, in relation to requiring a utilization review agent to follow certain rules when establishing a step therapy protocol

Purpose or general idea of bill

The purpose of this bill is to require certain patient protections for plans and utilization review agents to follow when establishing a step therapy protocol.

Summary of provisions

Section one amends section 4902 of the insurance law by adding two new paragraphs (14) and (15) that require a utilization review agent, when they are establishing a step therapy protocol, to ensure various proto- cols. These include prohibiting a prescription drug that has not been approved by the US FDA from being within a step therapy protocol. In addition, a protocol cannot require an insured to try and fail on more than one drug before providing coverage to the insured. A protocol cannot require the use of a step therapy-required drug for longer than 30 days.

Section one also states that a protocol cannot be imposed on an insured if they have taken the prescribed drug covered by a plan within the past 365 days. In addition, a step therapy protocol cannot require a newly enrolled insured to repeat step therapy for a prescribed drug where they have already completed a step therapy protocol for that drug under a different plan. Finally, a protocol cannot impose on an insured a prescribed drug that was previously approved by a plan for a specific medical condition after the insured's plan implements a formulary change.

This section also requires a utilization review agent to ensure that the protocol accepts any attestation submitted by the insured's health care professional stating that a required drug has failed.

Section two amends section 4903 of the insurance law to add that any approval of a step therapy protocol override determination request must be honored until 12 months after the date of approval or renewal of the plan.

Section two also states that if a utilization review agent fails to comply with any of the step therapy protocol requirements it will be considered as a basis for granting an override of that step therapy protocol.

Section three amends section 4902 of the public health law with the same requirements as section one.

Section four amends section 4903 of the public health law with the same requirements as section two.

Section five requires that this act shall take effect immediately.

Justification

These additional patient protections are intended to ensure that patients do not need to try and fail repeatedly on inappropriate medica- tions and that step therapy protocols to do not cause significant delays in access to the prescribed medication. Step therapy protocols that ignore prior failures or cause long delays can result in adverse events, including disease progression and relapse.

Prior legislative history

S8191 - 2022

Fiscal implications

None

Effective date

This act shall take effect immediately.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.